To get Wegovy covered by insurance, you generally need a diagnosis of obesity (BMI of 30 or higher) or overweight (BMI of 27 to 29.9) with at least one weight-related health condition. A separate cardiovascular indication also exists for people with established heart disease. The specific diagnosis your doctor documents, and the billing codes they use, directly determine whether your claim gets approved or denied.
The Two FDA-Approved Indications
Wegovy has two distinct approved uses, and each one opens a different coverage pathway. The first is chronic weight management in adults with obesity or adults with overweight plus at least one weight-related comorbidity. The second, approved in March 2024, is reducing the risk of heart attack, stroke, and cardiovascular death in adults who already have cardiovascular disease and are either obese or overweight.
For adolescents aged 12 and older, coverage requires a BMI at or above the 95th percentile for their age and sex. This is a higher bar than the adult criteria, since BMI in children is measured against growth charts rather than fixed numbers.
Qualifying Diagnoses for Weight Management
If your BMI is 30 or above, obesity alone is typically sufficient as the primary diagnosis. Your doctor doesn’t need to document any additional conditions. The BMI cutoffs break down into three severity classes: Class 1 obesity covers a BMI of 30 to just under 35, Class 2 covers 35 to just under 40, and Class 3 covers 40 and above.
If your BMI falls between 27 and 29.9, you need at least one weight-related comorbidity on your chart. The conditions that most commonly qualify include:
- High blood pressure (treated or untreated)
- High cholesterol or triglycerides (treated or untreated)
- Cardiovascular disease, including coronary heart disease
- Obstructive sleep apnea
- Prior heart attack or stroke
- Peripheral arterial disease
If you have one of these conditions but it hasn’t been formally diagnosed and coded in your medical records, ask your doctor to document it. Insurance companies match billing codes to coverage criteria, so an undocumented condition won’t help your claim.
The Cardiovascular Indication
The heart-related indication requires established cardiovascular disease, not just risk factors. “Established” means you’ve already had a heart attack, a stroke (ischemic or hemorrhagic), or you have symptomatic peripheral arterial disease. Simply having high blood pressure or high cholesterol doesn’t qualify under this pathway.
This distinction matters most for Medicare beneficiaries. Medicare Part D has historically excluded weight-loss drugs, but the cardiovascular indication gave plans a legal basis to cover Wegovy since it’s no longer being prescribed solely for weight loss. Coverage under Part D is allowed but not guaranteed, and plans vary in whether they’ve added it to their formularies. Monthly out-of-pocket costs for Medicare beneficiaries can run $325 to $430 before hitting the annual spending cap of $2,000.
Diagnoses That Can Disqualify You
Here’s where many people get tripped up: a diabetes diagnosis can actually block Wegovy coverage. UnitedHealthcare’s prior authorization criteria, which many commercial plans mirror, specifically exclude patients with a diabetes diagnosis or an A1C above 6.5%. The reasoning is that patients with type 2 diabetes should be prescribed a diabetes-indicated GLP-1 medication like Ozempic instead, which contains the same active ingredient but is approved for blood sugar management. If your chart includes a diabetes diagnosis, your insurer will likely steer you toward Ozempic rather than Wegovy.
Class IV heart failure, the most severe category where symptoms occur even at rest, is another disqualifying condition across most plans.
ICD-10 Codes Your Doctor Should Use
Insurance claims live and die by diagnostic codes. The CDC updated its recommended obesity codes in late 2024, and using the newer codes can improve your chances of smooth processing. Your doctor should pair one of the new obesity severity codes with a BMI Z-code:
- E66.811 for Class 1 obesity (BMI 30 to 34.9)
- E66.812 for Class 2 obesity (BMI 35 to 39.9)
- E66.813 for Class 3 obesity (BMI 40+)
These replace older codes like E66.01 and E66.09. The corresponding BMI Z-codes (Z68.30 through Z68.45) should be submitted alongside the E-code to confirm the specific BMI value. For overweight patients, the Z-code range Z68.25 through Z68.29 documents a BMI between 25 and 29.9, and the qualifying comorbidity needs its own separate code on the claim.
If your doctor’s office is still using the older obesity codes, it’s worth flagging the update. Some claims systems reject or delay processing when outdated codes appear.
Prior Authorization: What to Expect
Nearly every insurer requires prior authorization for Wegovy. The documentation your doctor typically needs to submit includes a BMI measurement taken within the last 90 days (based on a current height and weight, not a self-reported number), the relevant diagnosis codes, and confirmation that you don’t have an excluding condition like diabetes.
For the cardiovascular indication specifically, your doctor will need to document the qualifying cardiovascular event or condition. Maryland’s Medicaid program, as one example, requires evidence of a prior heart attack, prior stroke, or symptomatic peripheral arterial disease confirmed by clinical testing or a history of arterial procedures. Other state Medicaid programs and commercial insurers follow similar patterns.
Authorizations are commonly granted in six-month blocks. Your insurer will want to see that you’re still using the medication and that your prescriber reaffirms the qualifying diagnosis before renewing coverage for another six months.
Coverage Differences by Insurance Type
Commercial insurance through an employer or the marketplace is the most likely path to Wegovy coverage for weight management, though plans vary widely. Some cover it with a manageable copay, others place it on a specialty tier with 25% to 33% coinsurance, and some exclude weight-loss medications entirely.
Medicare Part D can now cover Wegovy, but only under the cardiovascular indication for patients with established heart disease. Coverage for weight management alone remains excluded under Medicare. Even for the cardiovascular use, individual Part D plans choose whether to add Wegovy to their formulary, so coverage isn’t automatic.
Medicaid coverage depends entirely on your state. Some state Medicaid programs cover anti-obesity medications with prior authorization, while others exclude them. If your state’s Medicaid program does cover Wegovy, the qualifying criteria tend to be narrower than commercial plans, often limited to the cardiovascular indication with documented heart disease, a BMI of at least 27, and no diabetes diagnosis.
What to Do if You’re Denied
If your prior authorization is denied, the denial letter will specify the reason. The most common issues are a missing comorbidity diagnosis for overweight patients, an outdated or insufficient BMI measurement, or a diabetes diagnosis that redirects you to Ozempic. In many cases, a corrected submission with proper documentation resolves the problem. Your doctor’s office can file a peer-to-peer review, where your prescriber speaks directly with the insurer’s medical reviewer to make the case for coverage. Appeals succeed often enough that they’re worth pursuing, especially when the denial stems from a documentation gap rather than a true exclusion.